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Risk of Second Primary Tumors in Men Diagnosed
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BACKGROUND: The survival of men diagnosed with prostate cancer has improved over time, and the current 10-year relative survival
rate is 99.7%. The long survival of patients with this common cancer raises questions about the risk of a second primary cancer and
the need for continued surveillance. METHODS: A population-based cohort of 441,504 men who were diagnosed with prostate cancer
between 1992 and 2010 was identified from Surveillance, Epidemiology and End Results Program (SEER) data (SEER13). The standar-
dized incidence ratio (SIR) was calculated as an estimate of the risk of a second primary malignancy based on the incidence in the
general population. RESULTS: Prostate cancer survivors had a lower risk of being diagnosed with another cancer overall compared
with the US population (SIR50.60; 95% confidence interval, 0.60-0.61). The risks of leukemia and cancers of the oral cavity and
pharynx, esophagus, stomach, colon and rectum, liver, gallbladder, pancreas, lung and bronchus, and larynx were significantly lower.
Conversely, these patients had a greater risk of bladder, kidney, and endocrine and soft tissue cancers. Men who received treatment
with radiation therapy (external-beam radiation therapy) had long-term increases in their risk of bladder cancer (SIR5 1.42) and rectal
cancer (SIR5 1.70) risk compared with who did not receive radiation (SIRbladder50.76; SIRrectal50.74). There were significant racial
differences in the risk of being diagnosed with a second primary cancer, and the magnitude and direction of these risks depended on
tumor type. CONCLUSIONS: Prostate cancer survivors remain at risk of subsequent malignancies, and race and treatment choice
important determinants of long-term risk. Cancer 2014;120:2735-41. VC 2014 American Cancer Society.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed noncutaneous malignancy among men in the United States.1 Since the
widespread adoption of screening with serum prostate-specific antigen (PSA), the majority of men are diagnosed with local-
ized disease. Combined with improvements in clinical therapies, the survival of men diagnosed with prostate cancer has
increased to the current estimates for 10-year and 15-year relative survival at 98% and 91%, respectively.2 The long life ex-
pectancy of these patients exposes them to the possibility of developing second primary malignancies. Second-order or
higher order malignancies affected 16% of cancer survivors as a whole in 2003.3 Risk factors for second malignancies are
multifactorial and can include treatment for the initial cancer, normal aging, lifestyle and environmental factors, and genetic
susceptibility. From a clinical perspective, the identification of patients who are at increased risk of experiencing subsequent
malignancies is important for optimizing treatment and may help identify those who would benefit from enhanced screen-
ing. With regard to genetic predisposition, cancers that occur together may help identify a more homogeneous phenotype
for future gene discovery efforts.
MATERIALS AND METHODS
Data Source
The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program database was used to iden-
tify the cohort of men for this study. The demographic and incidence data collected by the SEER registries generally are
Corresponding author: Kathleen A. Cooney, 7216 Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-5948; Fax: (734) 936-7376; kcooney@umich.edu
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan; 2University of Michigan Comprehensive Cancer Center, Ann Arbor,
Michigan; 3Karmanos Cancer Institute, Division of Population Studies and Disparities Research, Detroit, Michigan; 4Department of Oncology, Wayne State Univer-
sity, Detroit, Michigan; 5Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan
Additional supporting information may be found in the online version of this article.
We recognize the contribution of Dr. Claudia Salinas and the Epidemiology Research Core at Karmanos Cancer Institute toward this analysis and article.
DOI: 10.1002/cncr.28769, Received: January 6, 2014; Revised: April 9, 2014; Accepted: April 21, 2014, Published online May 19, 2014 in Wiley Online Library
(wileyonlinelibrary.com)
Cancer September 1, 2014 2735
Original Article
considered to be representative of the US population as a
whole.4,5 The SEER13 registry data are used by the
SEER*Stat software program (Surveillance Research Pro-
gram, National Cancer Institute, Bethesda, Md) to esti-
mate the incidence of secondary malignancies in the
prostate cancer cases and includes individual-level data
from 1992 to 2010 from 13 registries (Atlanta, Connecti-
cut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-
Oakland, Seattle-Puget Sound, Utah, Los Angeles, San
Jose-Monterey, Rural Georgia, and the Alaska Native Tu-
mor Registry). The SEER13 data cover 13.4% of the total
US population and 11.5%, and 11.3% of the total white
and black US population, respectively.
Study Population
The cohort was composed of 441,504 men who were
diagnosed with a first primary, microscopically con-
firmed, malignant prostate cancer (International Classifi-
cation of Diseases for Oncology third edition histology
classification codes for carcinoma not otherwise specified
[8010], nonsmall cell carcinoma [8046], adenocarcinoma
not otherwise specified [8140], cribriform carcinoma
[8201], adenocarcinoma with mixed subtypes [8255],
mucinous adenocarcinoma [8480], mucin-producing ad-
enocarcinoma [8481], and acinar cell carcinoma [8550])
who were reported to 1 of the 13 SEER registries between
January 1, 1992 and December 31, 2010. We excluded
cases that were reported only on death certificate or au-
topsy and those with unknown age at diagnosis. We re-
stricted the cohort to men aged 20 years to ensure that
men with early onset (aged <55 years at diagnosis) pros-
tate cancer would be captured.
Statistical Analysis
Second primary malignancies required a minimum 2-
month latency period after the primary diagnosis to
exclude synchronous primary cancers. Multiple primary
standardized incidence ratios (MP-SIRs) were calculated
as a measure of the relative risk of a second primary malig-
nancy using SEER*Stat software version 8.0.4. More
detailed information on both SEER*Stat software and the
method the software uses to derive the standard incidence
ratios (SIRs) are available on the SEER registry website
(available at: http:==seer.cancer.gov=seerstat=; accessed
March 14, 2014).6 Specifically, the observed incidence of
second malignancy among men previously diagnosed with
prostate cancer was compared with the expected incidence
based on the corresponding segment of the US general
population (ie, similarly aged white men and black men in
the SEER13 geographic areas). In addition, because the
survival of patients initially diagnosed with distant stage
disease would be considerably shorter than the survival of
patients diagnosed with locoregional disease, we performed
a separate analysis excluding the patients who had distant
disease at time of diagnosis.
Analyses were stratified by age at prostate cancer di-
agnosis (early onset [ages 20-54 years] or late onset [aged
55 years]), race (white or black), latency period (2-11
months, 12-59 months, 60-120months, or>120 months
from the date of prostate cancer diagnosis), and calendar
period of prostate cancer diagnosis (1992-2000 or 2001-
2010). Results also were considered according to whether
or not men received radiation therapy (external-beam
radiation therapy [EBRT]) as their initial treatment for
prostate cancer. In the SEER database, the first treatment
received in the year after prostate cancer diagnosis is
recorded as the primary treatment. For this particular
analysis, only second primary tumors that were diagnosed
>120 months after the original date of prostate cancer di-
agnosis were eligible. The risk of being diagnosed with a
second cancer among patients with prostate cancer, as
opposed to the general population, was compared
between the aforementioned groups using either the chi-
square goodness-of-fit test (or Fisher exact test) or an eval-
uation of the confidence intervals (CIs) between groups to
determine any overlap. A 2-sided P value< .05 was con-
sidered statistically significant.
RESULTS
We identified 441,504 men who were diagnosed with
prostate cancer between January 1, 1992 and December
31, 2010 from the SEER13 geographic areas. Men were
aged 20 years at the time of prostate cancer diagnosis,
and the majority of cancers were diagnosed between ages
65 and 74 years. Of these, 44,310 men (10%) developed a
second primary malignancy during the observation period
(Table 1). Compared with cancer incidence in the general
population, men with prostate cancer had a lower risk
overall for a second primary malignancy (SIR5 0.60;
95% CI, 0.60-0.61), which was slightly lower for solid
tumors (SIR5 0.57; 95% CI, 0.56-057) than for other
invasive cancers. The reductions in risk were significant
for leukemia and for cancers of the oral cavity and phar-
ynx, esophagus, stomach, colon and rectum, liver, gall-
bladder, pancreas, lung and bronchus, and larynx.
Conversely, there were significant increases in risk for can-
cers of soft tissue including heart, bladder, kidney, and en-
docrine system among men with prostate cancer
compared with the general population. Because the data
cover a wide period of time, during which diagnostic and
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treatment methods may have changed, we considered
whether there were differences by calendar period of the
data (1992-2000 vs 2001-2010). The only important dif-
ferences observed by calendar period were for kidney can-
cer in prostate cancer patients, for which the risk increased
in the recent era (SIR1992-20005 1.01 [95% CI, 0.95-
1.06] vs SIR2001-20105 1.32 [95% CI, 1.24-1.41]).
Repeat analyses removing those men who had prostate
cancer initially diagnosed as distant stage disease did not
materially change the risk estimates (data not shown).
Latency
In the 2 to 11 months after prostate cancer diagnosis,
there was an increased risk of urinary bladder, kidney,
thyroid, and endocrine system cancers and of lymphoma
(including both Hodgkin and non-Hodgkin lymphoma).
At >120 months from diagnosis, the risk was decreased
for all of these malignancies among all patients (see online
Supporting Information)
Age at Prostate Cancer Diagnosis
We considered whether the age of prostate cancer diagno-
sis (ie, early onset vs late onset) modified the risk of second
primary malignancies. Men with early onset prostate can-
cer had a modestly higher risk of both bladder cancer
(SIR5 1.29; 95% CI, 1.10-1.51) and thyroid cancer
(SIR5 1.63; 95% CI, 1.19-2.18) compared with men in
the general population and in contrast to men who were
diagnosed at older ages (bladder cancer, SIR5 1.04 [95%
CI, 1.01-.07]; thyroid cancer, SIR5 1.02 [95% CI, 0.90-
1.15]).
Race
There were significant differences in the relative risk esti-
mates between blacks and whites for several cancer sites
(Table 2). The risks of a secondary diagnosis of stomach,
colon, bladder, and kidney cancers and of leukemia—par-
ticularly chronic lymphocytic leukemia—all were higher
in black men who had prostate cancer compared with
white men who had prostate cancer. Likewise, the reduc-
tion in risk was significantly less in black patients com-
pared with white patients for cancers of the lung and
bronchus. It is noteworthy that there was a reversal in the
direction of the SIRs for chronic lymphocytic leukemia
and colon cancer, in which black men with prostate cancer
had significant increase in the risk for both cancers
(SIR5 1.27 and SIR5 1.10, respectively) compared with
the general population, whereas white men with prostate
cancer had a significantly reduced risk (SIR5 0.87 and
SIR5 0.88, respectively). There were no cancers for
which the relative risk estimates among white men with
prostate cancer were higher than those for black men with
prostate cancer.
Initial Therapy for Prostate Cancer
Finally, we considered the influence of radiation therapy
for prostate cancer on the subsequent risk of developing
new malignancies (Table 3). For this analysis, we only
considered new primary cancers that arose10 years after
prostate cancer treatment. In the cohort of 106,879
patients who were still under observation at that time, the
SIRs were compared between the 66.7% of patients who
did not receive radiation as their initial therapy for pros-
tate cancer and the 23.9% who had a record of receiving
EBRT. The remaining patients received radioactive seed
implants (4.5%) or unspecified/combined radiotherapies
(4.9%). Compared with men who did not receive
TABLE 1. Risk of a Second Malignancy in US Men
Diagnosed With Prostate Cancer (1992-2010), by
Tumor Site
Second Tumor Sitea Obsb Expc SIR (95% CI)d
All sites 44,310 73,262 0.60 (0.60-0.61)
All solid tumors 36,852 65,185 0.57 (0.56-0.57)
Oral cavity and pharynx 1251 1647 0.76 (0.72-0.80)
Esophagus 842 1040 0.81 (0.76-0.87)
Stomach 1392 1609 0.87 (0.82-0.91)
Small intestine 315 297 1.06 (0.95-1.18)
Colon excluding rectum 5113 5709 0.90 (0.87-0.92)
Rectum and rectosigmoid
junction
1967 2088 0.94 (0.90-0.98)
Liver 637 1040 0.61 (0.57-0.66)
Gallbladder 104 128 0.81 (0.66-0.99)
Pancreas 1781 1913 0.93 (0.89-0.98)
Lung and bronchus 8615 11,158 0.77 (0.76-0.79)
Soft tissue including heart 407 357 1.14 (1.03-1.26)
Melanoma of the skin 2681 2710 0.99 (0.95-1.03)
Male breast 142 161 0.88 (0.74-1.04)
Urinary bladder 5885 5620 1.05 (1.02-1.07)
Kidney 2213 1980 1.12 (1.07-1.17)
Brain 631 614 1.03 (0.95-1.11)
Endocrine system 440 393 1.12 (1.02-1.23)
Thyroid 372 337 1.10 (1.00-1.22)
Lymphoma 2935 2985 0.98 (0.95-1.02)
Hodgkin lymphoma 118 140 0.85 (0.70-1.01)
NHL 2817 2846 0.99 (0.95-1.03)
Myeloma 1078 1091 0.99 (0.93-1.05)
Leukemia 1906 2098 0.91 (0.87-0.95)
Larynx 651 806 0.81 (0.75-0.87)
Abbreviations: CI, confidence interval; Exp, expected; NHL, non-Hodgkin
lymphoma; Obs, observed; SIR, standard incidence ratio.
a Boldface indicates tumor sites for which the SIR was significantly
different.
b Second primary malignancies diagnosed within 2 months of the initial
prostate cancer diagnosis were not included.
c Expected malignancies were estimated from the incidence rate at the tu-
mor sites in the general US population.
dUnadjusted SIRs were based on 2,889,094 person-years at risk
(n5 441,504).
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radiation, men who received EBRT were significantly
more likely than the general population to be diagnosed
with rectal cancer (SIRradiation5 1.70 vs
SIRnoradiation5 0.74; P< .0001) and bladder cancer
(SIRradiation5 1.42 vs SIRnoradiation5 0.76; P< .0001).
Both groups were at reduced risk of second primary
malignancy and second solid tumors overall, but the mag-
nitude of the reduction was less among men who received
radiation (eg, for solid tumors, SIR5 0.72 [95% CI,
0.69-.76] among those who received EBRT compared
with SIR5 0.51 [95% CI, 0.49-0.52] for those who were
not exposed to radiation).
DISCUSSION
Overall, we observed that prostate cancer survivors had a
40% lower risk of developing a second primary cancer
compared with the general US male population. Specifi-
cally, they had a lower risk of developing leukemia and
cancers of the oral cavity and pharynx, esophagus, stom-
ach, colon and rectum, liver, gallbladder, pancreas, lung
and bronchus, and larynx. In contrast, men with prostate
cancer had a higher risk of developing bladder, kidney,
soft tissue, and endocrine cancers. The reduction in over-
all cancer risk in these patients is consistent with previous
studies.7-11 Although the reasons for the reduction in risk
are not entirely clear, they may relate in part to the age of
patients at the time of diagnosis of prostate cancer. Cur-
rently the mean age at diagnosis is 67 years1; however, the
age at diagnosis has declined over the past few decades pri-
marily because of PSA screening and earlier detection of
preclinical cancers. Nevertheless, older men who have
prostate cancer, particularly men with competing risks for
death, may not have the same opportunity for a second di-
agnosis as all US men. Conversely, the increased risk of
certain cancers may be explained by enhanced surveillance
and screening after a prostate cancer diagnosis, leading to
detection of latent malignancies.10 This idea is supported
by the existence of a strong temporal effect on kidney
TABLE 2. Risk of Second Malignancy in US Men Diagnosed With Prostate Cancer, by Race
White, n5 345,585 Black, n557,362
Second Tumor Sitea Obsb Expc SIR (95% CI)d Obsb Expc SIR (95% CI)d
All sites 36,138 59094 0.61 (0.61-0.62) 5764 9431 0.61 (0.60-0.63)
All solid tumors 29,874 52316 0.57 (0.56-0.58) 4922 8637 0.57 (0.55-0.59)
Oral cavity and pharynx 1039 1353 0.77 (0.72-0.82) 155 194 0.8 (0.68-0.93)
Esophagus 691 845 0.82 (0.76-0.88) 116 133 0.87 (0.72-1.04)
Stomach 926 1139 0.81 (0.76-0.87) 275 254 1.08 (0.96-1.22)
Small intestine 225 227 0.99 (0.87-1.13) 67 53 1.26 (0.98-1.61)
Colon excluding rectum 3988 4538 0.88 (0.85-0.91) 835 757 1.1 (1.03-1.18)
Rectum and rectosigmoid junction 1591 1686 0.94 (0.9-0.99) 246 229 1.07 (0.94-1.22)
Liver 424 716 0.59 (0.54-0.65) 127 165 0.77 (0.64-0.91)
Gallbladder 74 97 0.76 (0.6-0.95) 21 15 1.36 (0.84-2.07)
Pancreas 1375 1509 0.91 (0.86-0.96) 272 260 1.05 (0.93,1.18)
Lung and bronchus 6635 8775 0.76 (0.74-0.77) 1483 1609 0.92 (0.88-0.97)
Soft tissue including heart 342 303 1.13 (1.01-1.25) 44 29 1.52 (1.11-2.04)
Melanoma of the skin 2641 2611 1.01 (0.97-1.05) 17 17 1.00 (0.58-1.6)
Male breast 115 130 0.88 (0.73-1.06) 21 23 0.92 (0.57-1.41)
Urinary bladder 5194 4972 1.04 (1.02-1.07) 430 334 1.29 (1.17-1.41)
Kidney 1707 1589 1.07 (1.02-1.13) 401 279 1.43 (1.30-1.58)
Brain 554 543 1.02 (0.94-1.11) 50 39 1.29 (0.96-1.7)
Endocrine system 360 324 1.11 (1.00-1.23) 45 37 1.22 (0.89-1.64)
Thyroid 315 283 1.11 (0.99-1.24) 29 28 1.04 (0.69-1.49)
Lymphoma 2552 2572 0.99 (0.95-1.03) 225 208 1.08 (0.95-1.23)
Hodgkin lymphoma 105 120 0.87 (0.71-1.06) 10 12 0.85 (0.41-1.56)
NHL 2447 2452 1.00 (0.96-1.04) 215 196 1.10 (0.95-1.25)
Myeloma 793 815 0.97 (0.91-1.04) 245 215 1.14 (1.00-1.29)
Leukemia 1609 1808 0.89 (0.85-0.93) 213 174 1.22 (1.06-1.4)
CLL 724 835 0.87 (0.80-0.93) 96 76 1.27 (1.03-1.55)
AML 472 481 0.98 (0.89-1.07) 69 49 1.41 (1.10-1.27)
Larynx 490 622 0.79 (0.72-0.86) 142 144 0.99 (0.83-1.17)
Abbreviations: ALL, acute myeloid leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; Exp, expected; NHL, non-Hodgkin lymphoma; Obs,
observed; SIR, standard incidence ratio.
a Boldface indicates those tumor sites with statistically significant group differences.
b Second primary malignancies diagnosed within 2 months of the initial prostate cancer diagnosis were not included.
c Expected malignancies were estimated from the incidence rate at the tumor sites in the general US population.
dUnadjusted standardized incidence ratio (SIR) based on 2,308,454 (White) and 351,384 (Black) person-years at risk, respectively.
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cancer risk, with a sharp increase in risk restricted to the
year immediately after the initial prostate cancer diagnosis
(see online Supporting Information).
Exposure to ionizing radiation is a known risk factor
for cancer. Our current findings suggest that patients with
prostate cancer who receive radiation therapy are at an
increased risk of being diagnosed with certain cancers,
particularly cancers of the bladder and rectum. The obser-
vation of an increase in risk among patients >10 years af-
ter their initial prostate cancer diagnosis highlights the
need for continued surveillance of these patients. The
occurrence of hematuria and hematochezia should be
promptly evaluated. Our investigation is largely in agree-
ment with earlier studies, which examined the risk of sec-
ond primaries associated with receipt of radiation therapy;
however, the current study examines the risk of all invasive
cancers with a longer follow-up period and examines a
greater number of biologically plausible latency intervals.
Moon et al observed an increased risk of bladder cancer af-
ter EBRT versus brachytherapy.12 Those authors also
observed an increased risk of melanoma and cancers of the
rectum, cecum, transverse colon, brain, stomach, and
lung and bronchus among men who received EBRT com-
pared with those who did not receive radiation, but they
did not observe an increased risk of second malignancy
among those who received radioactive implants or iso-
topes. That study had a 5-year exclusion time and a 10.6-
year follow-up period. Brenner et al observed that, com-
pared with surgery, radiotherapy was associated with a
small increase in the risk of solid tumors.13 The most sig-
nificant increases in risk were for bladder cancer, rectal
cancer, and lung cancer, and sarcomas. The exclusion pe-
riod in that study was 2 months, and patients were fol-
lowed for 4 years on average. However, Abdel-Wahab
et al compared EBRT with brachytherapy and noted no
significant increase in the risk of second primaries among
TABLE 3. Risk of Second Malignancy in US Men Diagnosed With Prostate Cancer, by Primary Prostate
Cancer Treatment
No Radiation, n571,242 EBRT, n5 25,569
Second Tumor Sitea Obsb Expc SIR (95% CI)d Obsb Expc SIR (95% CI)d Pe
All sites 4017 7353 0.55 (0.53-0.56) 1880 2494 0.75 (0.72-0.79) < .0001
All solid tumors 3272 6452 0.51 (0.49-0.52) 1566 2166 0.72 (0.69-0.76) < .0001
Oral cavity and pharynx 98 152 0.64 (0.52-0.79) 39 49 0.79 (0.56-1.08) .58
Esophagus 79 107 0.74 (0.58-0.92) 31 36 0.86 (0.59-1.23) .67
Stomach 135 164 0.83 (0.69-0.98) 54 62 0.87 (0.65-1.14) .50
Small intestine 38 33 1.15 (0.82-1.58) 16 12 1.38 (0.79-2.25) .59
Colon excluding rectum 415 576 0.72 (0.65-0.79) 198 213 0.93 (0.80-1.07) .009
Rectum and rectosigmoid junction 142 192 0.74 (0.62-0.87) 112 66 1.7 (1.40-2.04) < .0001
Liver 47 105 0.45 (0.33-0.60) 17 35 0.49 (0.28-0.78) .98
Gallbladder 16 15 1.07 (0.61-1.74) 2 6 0.35 (0.04-1.28) .18
Pancreas 172 216 0.8 (0.68-0.93) 77 78 0.98 (0.78-1.23) .11
Lung and bronchus 770 1138 0.68 (0.63-0.73) 344 393 0.88 (0.79-0.97) .0007
Soft tissue including heart 42 42 1.01 (0.73-1.36) 21 15 1.42 (0.88-2.16) .21
Melanoma of the skin 282 330 0.86 (0.76-0.96) 94 111 0.85 (0.69-1.04) .53
Male breast 14 18 0.78 (0.43-1.31) 6 6 0.94 (0.34-2.05) .8
Urinary bladder 506 662 0.76 (0.70-0.83) 343 241 1.42 (1.28,1.58) < .0001
Kidney 220 209 1.05 (0.92-1.20) 72 67 1.07 (0.84-1.35) .50
Brain 51 62 0.82 (0.61-1.08) 18 20 0.88 (0.52-1.40) .95
Endocrine system 36 41 0.88 (0.62-1.22) 12 12 0.99 (0.51-1.72) .82
Thyroid 30 35 0.86 (0.58-1.22) 10 10 0.97 (0.47-1.79) .84
Lymphoma 280 334 0.84 (0.74-0.94) 122 116 1.05 (0.87-1.25) .07
Hodgkin lymphoma 7 14 0.49 (0.20-1.01) 5 5 1.07 (0.35-2.51) .32
NHL 273 320 0.85 (0.760.96) 117 112 1.05 (0.87-1.25) .11
Myeloma 128 120 1.07 (0.89-1.27) 47 43 1.09 (0.80-1.45) .89
Leukemia 220 238 0.92 (0.80-1.05) 77 87 0.88 (0.70-1.10) .85
CLL 102 111 0.92 (0.75-1.12) 35 40 0.88 (0.61-1.22) .82
AML 68 65 1.04 (0.81-1.32) 20 24 0.83 (0.51-1.29) .43
Larynx 53 74 0.72 (0.54-0.94) 28 24 1.18 (0.78-1.70) .10
Abbreviations: ALL, acute myeloid leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; EBRT, external-beam radiation therapy; Exp,
expected; NHL, non-Hodgkin lymphoma; Obs, observed; SIR, standard incidence ratio.
a Boldface indicates those tumor sites with statistically significant group differences.
b Second primary malignancies diagnosed within 10 years of the initial prostate cancer diagnosis were not included.
c Expected malignancies were estimated from the incidence rate at the tumor sites in the general US population.
dUnadjusted SIRs were based on 259,054 (no radiation) and 83,793 (EBRT) person-years at risk.
eP values were calculated from chi-square goodness of fit tests or Fisher exact tests (Hodgkin lymphoma, gallbladder, male breast) by comparing the cumula-
tive incidence for each specific second primary between patients with prostate cancer patients who received EBRT or no radiation (observed/n).
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patients who received radiation.14 Smaller studies have
reported on the connection between radiation therapy
and the risk of a second primary cancer with mixed
results.15-21 Neugut et al22 used SEER data to investigate
the risk of secondary malignancy after a prostate cancer di-
agnosis and observed an increased risk of bladder cancer
and chronic lymphocytic leukemia, but not of rectal can-
cer or acute nonlymphocytic leukemia, among men who
received radiation. It is noteworthy that the risk of bladder
cancer increased with greater time from treatment, rang-
ing from a relative risk (RR) of 1.0 (95% CI, 0.8-1.2)
from 6 months to 5 years after treatment, to an RR of 1.3
(95% CI, 1.0-1.7) from 5 to 8 years after treatment, and
to an RR of 1.5 (95% CI, 1.0-2.0) >8 years after treat-
ment, similar to our current results. Similarly, Baxter
et al23 studied the effect of radiation on the risk of devel-
oping colorectal cancer at 3 different sites: rectum, recto-
sigmoid/sigmoid/cecum, and the rest of the colon.
Similar to the current findings, those authors noted a sig-
nificantly increased risk of rectal cancer among men who
received radiation, with a hazard ratio of 1.7 (95% CI,
1.4-2.2), compared with men who did not receive radia-
tion. There was no increased risk of cancer in the rest of
the colon. Those authors excluded patients who had been
diagnosed within 5 years of their initial prostate cancer di-
agnosis, and the patients were under observation for
approximately 9 years.
There are many different management options for
patients with localized prostate cancer, including radical
prostatectomy, radiation therapy (EBRT and/or brachy-
therapy), and active surveillance. The selection of an
approach is based on the physician’s assessment of cancer
risk and life expectancy as well as patient preferences. Our
findings of increased risks of secondary bladder and rectal
cancers among men who receive radiation for the manage-
ment of localized prostate cancer may have an impact on
the discussions between providers and their patients. It
should be noted, however, that the absolute risk for both
of these cancers in this setting is small.
Although we observed that prostate cancer survivors
were at a reduced risk for a second primary, black men
with prostate cancer tended to have greater risk compared
with white men. For example, black men with prostate
cancer did not exhibit the same magnitude of risk reduc-
tion for lung cancer observed for white men with prostate
cancer. For malignancies with higher incidence among
men with prostate cancer, the risk among black prostate
cancer survivors was even higher, (eg, bladder and kid-
ney). Racial disparities in prostate cancer risk and mortal-
ity are established.24,25 However, to our knowledge, racial
differences in the risk of second malignancy have not been
reported previously. The etiology of the racial disparity
observed in our study is not evident and may reflect differ-
ences in genetic susceptibility or environmental exposures,
treatment received, or some combination of these factors.
Further investigation will be required to understand this
additional source of disparity for black men diagnosed
with prostate cancer.
Strengths of this study include the use of a large,
population-based design, which allows the results to be
generalized across the United States. SEER data benefit
from well defined data collection and extensive quality
standards designed to assure that all eligible cases are cap-
tured5 and that under-ascertainment of second primaries
will be low. Potential limitations include the lack of
detailed information available on treatment for prostate
cancer other than the initial therapy received in the first
year after diagnosis and on lifestyle factors and comorbid-
ities other than cancer. In this study, misclassification of
the treatment received probably would have been nondif-
ferential and, thus, would have led to an underestimate of
the actual risk of second primary malignancies associated
with radiation therapy. Finally, the number of statistical
tests performed to estimate the risk of a second primary by
tumor type does increase the likelihood of observing a sig-
nificant finding by chance alone, suggesting that these
results should be interpreted with some caution.
In summary, the results from this study suggest that,
although the risk of developing a secondary primary can-
cer among men with prostate cancer is lower than that in
the general population, prostate cancer survivors remain
at risk of certain malignancies, particularly for cancers
that are likely to be influenced by radiation treatment for
prostate cancer. Significant racial disparities also were
detected, suggesting that black men with prostate cancer
are more likely to experience second malignancies than
their white counterparts. These findings have direct clini-
cal implications and suggest a need for continued cancer
surveillance among prostate cancer survivors.
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